Facts of Keytruda 50 mg/vial ?
- Medicine Name: Keytruda 50 mg/vial
- Date of Approval: 04.09.2014
- Company Name: Merck & Co., Inc.
KEYTRUDA® (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
Administer 2 mg/kg as an intravenous infusion over 30 minutes every 3 weeks
Dilute prior to intravenous infusion
The most common side effects of KEYTRUDA include: feeling tired, cough, nausea, itching, rash, decreased appetite, constipation, joint pain, diarrhoea.
KEYTRUDA for injection (lyophilized powder): carton containing one 50 mg single-use vial (NDC 0006-3029-02).
KEYTRUDA injection (solution): carton containing one 100 mg/4 mL (25 mg/mL), single-use vial (NDC 0006-3026-02)
Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
Country of Import: USA